SWOG/NRG Joint Study: A Randomized Phase III Trial of Induction/ Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
Principal Investigator
Charles B. Simone II, MD,
Status
Closed to Accrual
Date Opened To Accrual
March 26 2020
Date Closed to Accrual
September 06 2024
Disease Site
Lung [LU]
Non-small Cell Lung Cancer
Phase
III
Developmental Therapeutics
No
Primary Objective
To compare overall survival (OS) in patients with inoperable, early stage non-small cell lung cancer (NSCLC) randomized to stereotactic body radiation therapy (SBRT) with or without atezolizumab.
NOTE:
This is a joint SWOG & NRG Oncology FDA registration-intent trial. NRG Oncology institutions can credit NRG for their case accrual.
SWOG Study Chair: Megan E. Daly, M.D.
Patient Population
Patients must have histologically or cytologically proven Stage I-IIA or limited T3N0M0 non-small cell lung cancer (NSCLC) without radiographic evidence of nodal or distant involvement (N0M0). Patients may have T3 disease with the exclusion of multifocal tumors and pericardial involvement.
Target Accrual
480
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.